目的:评估内皮型一氧化氮合酶(Endothelial nitric oxide synthase,eNOS)基因治疗对大鼠缺血后肢血管新生的影响。方法:局麻下将30只雄性SD大鼠后肢缺血模型制作后,随机分成实验组和对照组,每组15只。模型制作后1周,采用肌肉注射的方法...目的:评估内皮型一氧化氮合酶(Endothelial nitric oxide synthase,eNOS)基因治疗对大鼠缺血后肢血管新生的影响。方法:局麻下将30只雄性SD大鼠后肢缺血模型制作后,随机分成实验组和对照组,每组15只。模型制作后1周,采用肌肉注射的方法,实验组缺血后肢接受载有eNOS基因的5型重组腺病毒治疗,对照组接受生理盐水治疗。eNOS基因治疗后4周,评估SD大鼠踝部动脉压、微循环灌注、数字减影血管造影、组织微血管计数以及eNOS蛋白的表达。结果:eNOS基因治疗后4周,和对照组相比,接受eNOS基因治疗的大鼠缺血肢体,表现了更好的血流恢复(踝部动脉压(mmHg):58.2±4.7 vs 86.8±4.3,P<0.01;微循环灌注:142.0%±21.5%vs 219.6%±26.2%,P<0.01)、侧枝开放和血管新生(血管造影:6.7±1.1 vs 14.4±1.7,P<0.01;微血管/肌纤维比值:0.34±0.03 vs 0.56±0.02,P<0.01)以及eNOS蛋白的高表达(0.46±0.02 vs 0.73±0.02,P<0.01)。结论:eNOS基因治疗促进SD大鼠缺血后肢的血管新生。展开更多
Objective:To evaluate the efficacy of deep vein thrombosis(DVT)prevention among realworld surgical inpatients who received panax notoginseng saponins(PNS)combined with low-molecularweight heparin(LMWH).Methods:A prosp...Objective:To evaluate the efficacy of deep vein thrombosis(DVT)prevention among realworld surgical inpatients who received panax notoginseng saponins(PNS)combined with low-molecularweight heparin(LMWH).Methods:A prospective cohort study was conducted among surgical patients between January 2016 and November 2018 in Xuanwu Hospital,Capital Medical University,Beijing,China.Participants received LMWH alone or PNS combined with LMWH for preventing DVT.The primary outcome was incidence of lower extremity DVT,which was screened once a week.Participants in the LMWH group were given LMWH(enoxaparin)via hypodermic injection,4000-8000 AxalU once daily.Participants in the exposure group received PNS(Xuesaitong oral tablets,100 mg,3 times daily)combined with LMWH given the same as LMWH group.Results:Of the 325 patients screened for the study,281 participants were included in the final analysis.The cohort was divided into PNS+LMWH group and LMWH group with 134 and 147 participants,respectively.There was a significant difference of DVT incidence between two groups(P=0.01),with 21(15.7%)incident DVT in the PNS+LMWH group,and 41(27.9%)incident DVT in the LMWH group.Compared with participants without DVT,the participants diagnosed with DVT were older and had higher D-dimer level.The multivariate logistic regression moclel showed a significant lower risk of incident DVT among participants in the PNS+LMWH group compared with the LMWH group(odds ratio 0.46,95%confidence interval,0.25-0.86).There were no significant differences in thromboelaslography values(including R,K,Angle,and MA)and differences in severe bleeding between two groups.No symptomatic pulmonary embolism occurred during the study.Conclusion:Combined application of PNS and LMWH can effectively reduce the incidence of DVT among surgical inpatients compared with LMWH monotherapy,without increased risk of bleeding.展开更多
文摘目的:评估内皮型一氧化氮合酶(Endothelial nitric oxide synthase,eNOS)基因治疗对大鼠缺血后肢血管新生的影响。方法:局麻下将30只雄性SD大鼠后肢缺血模型制作后,随机分成实验组和对照组,每组15只。模型制作后1周,采用肌肉注射的方法,实验组缺血后肢接受载有eNOS基因的5型重组腺病毒治疗,对照组接受生理盐水治疗。eNOS基因治疗后4周,评估SD大鼠踝部动脉压、微循环灌注、数字减影血管造影、组织微血管计数以及eNOS蛋白的表达。结果:eNOS基因治疗后4周,和对照组相比,接受eNOS基因治疗的大鼠缺血肢体,表现了更好的血流恢复(踝部动脉压(mmHg):58.2±4.7 vs 86.8±4.3,P<0.01;微循环灌注:142.0%±21.5%vs 219.6%±26.2%,P<0.01)、侧枝开放和血管新生(血管造影:6.7±1.1 vs 14.4±1.7,P<0.01;微血管/肌纤维比值:0.34±0.03 vs 0.56±0.02,P<0.01)以及eNOS蛋白的高表达(0.46±0.02 vs 0.73±0.02,P<0.01)。结论:eNOS基因治疗促进SD大鼠缺血后肢的血管新生。
基金Supported by Beijing Traditional Chinese Medicine Technology Development Fund Project(No.JJ2015-09)Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(No.ZYLX201706)。
文摘Objective:To evaluate the efficacy of deep vein thrombosis(DVT)prevention among realworld surgical inpatients who received panax notoginseng saponins(PNS)combined with low-molecularweight heparin(LMWH).Methods:A prospective cohort study was conducted among surgical patients between January 2016 and November 2018 in Xuanwu Hospital,Capital Medical University,Beijing,China.Participants received LMWH alone or PNS combined with LMWH for preventing DVT.The primary outcome was incidence of lower extremity DVT,which was screened once a week.Participants in the LMWH group were given LMWH(enoxaparin)via hypodermic injection,4000-8000 AxalU once daily.Participants in the exposure group received PNS(Xuesaitong oral tablets,100 mg,3 times daily)combined with LMWH given the same as LMWH group.Results:Of the 325 patients screened for the study,281 participants were included in the final analysis.The cohort was divided into PNS+LMWH group and LMWH group with 134 and 147 participants,respectively.There was a significant difference of DVT incidence between two groups(P=0.01),with 21(15.7%)incident DVT in the PNS+LMWH group,and 41(27.9%)incident DVT in the LMWH group.Compared with participants without DVT,the participants diagnosed with DVT were older and had higher D-dimer level.The multivariate logistic regression moclel showed a significant lower risk of incident DVT among participants in the PNS+LMWH group compared with the LMWH group(odds ratio 0.46,95%confidence interval,0.25-0.86).There were no significant differences in thromboelaslography values(including R,K,Angle,and MA)and differences in severe bleeding between two groups.No symptomatic pulmonary embolism occurred during the study.Conclusion:Combined application of PNS and LMWH can effectively reduce the incidence of DVT among surgical inpatients compared with LMWH monotherapy,without increased risk of bleeding.
